Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Recent legal developments have highlighted the importance of advance planning for end-of-life care.

A Living Will is something every adult should consider discussing and creating at some point.

Conversations within families about individual preferences in the event of a terminal illness are an important first step, and these discussions should take place while everyone is still in good health.

Individuals may have very different views about how they wish to be treated if they develop a terminal illness or certain severe, irreversible conditions. For instance, some may not want ventilator support, while others may choose to avoid ICU care.

Some might accept ICU care but prefer not to undergo CPR. Others may prefer not to receive artificial feeding through tubes. Yet others may wish for every possible treatment to be attempted. A few may prefer to spend their final days at home.

Creating A Living Will

It should be noted that a Living Will does not impose any limitation on treatment for common medical conditions such as infections, surgery for curable illnesses, or routine hospital care.

These preferences apply only to situations such as terminal illness—for example, advanced cancer—or irreversible conditions such as a persistent vegetative state.

Creating a Living Will is now relatively straightforward. It must be signed in the presence of two witnesses and attested by a notary or a gazetted officer.

The earlier requirement of countersignature by a Judicial Magistrate has been removed to make the process easier. Templates are also available online that individuals can use as a basis for drafting their own. Before preparing one, it is helpful to discuss the pros and cons of their choices with the family doctor.

It is important to again emphasize that a Living Will is NOT about refusing all treatment, hospitalization, or ICU admission for routine medical care. Rather, it addresses only specific situations.

When such preferences are clearly documented in advance, important decisions about withholding or withdrawing treatment in select circumstances become less contentious.

Doctors and hospitals will no longer be hesitant to withhold unnecessary treatment measures in such situations, as it will already be documented in the patient’s own Living Will. Relatives also will not face the difficult decision of withholding or withdrawing futile medical treatment on behalf of their loved one.

Essentially, the Living Will protects the patient’s wishes when they are no longer able to speak for themselves.

What Happens Without A Living Will

In a terminally ill patient who is unable to communicate, the absence of a Living Will often leads to differences of opinion among family members about what the patient might have wanted.

This uncertainty frequently results in a collective decision to “do everything possible,” just to be on the safe side.

Doctors are reluctant to override the wishes of relatives, even when they believe that further treatment measures are unlikely to be beneficial.

As a result, the patient may receive prolonged medical interventions that neither improve the underlying condition nor enhance quality of life. Once started, these treatments may continue indefinitely until the patient dies naturally.

This may take months, years, or even decades, and also incur huge costs. In the absence of a Living Will, complex legal procedures are required to withdraw these treatments — even if all the relatives are convinced that they should be withdrawn.

India's drug regulator, the Central Drugs Standard Control Organization (CDSCO), has threatened pharmaceutical firms with action for promoting GLP-1 weight-loss drugs among the general public.

Glucagon-Like Peptide-1 (GLP-1) receptor agonists are a class of medicines that help lower blood sugar, support weight loss, reduce the risk of heart and kidney complications, and can even lower the risk of early death in people with type 2 diabetes.

In an official circular, the CDSCO warned drug makers from indulging in "direct or indirect advertising" for obesity and metabolic disorders.

The regulatory body also cautioned pharma companies against campaigns using influencers, noting that any violation "could attract regulatory action".

Advertisements, which "function as a surrogate advertisement for prescription-only drugs, shall be viewed seriously and may be treated as irrational or misleading marketing practice", read the letter signed by the Drug Controller General of India (DCGI) Rajeev Raghuvanshi.

The order comes as the CDSCO noted that drugmakers have been engaging in surrogate promotional activities, under the garb of disease awareness campaigns, and digital media outreach.

What The CDSCO Mandated

• Weight-loss drugs, specifically GLP-1 medications, must only be sold with a prescription from a registered medical practitioner.

• There should be no ads, whether direct or indirect, in print, electronic, digital, social media, or any other public platform intended, directly or indirectly, to promote the product to the general public.

• No GLP-1 drugs must exaggerate for therapeutic efficacy; suggest for assured or guaranteed weight loss outcome; and induce demand for pharmacological therapy

• awareness campaigns
• influencer engagement
• corporate campaigns

Rush For Generic Weight Loss Drugs

The government's advisory comes patent for semaglutide -- an active ingredient in diabetes and anti-obesity drugs, specifically Wegovy and Ozempic -- expires on March 20.

This will allow Indian pharma companies to launch cheaper generic versions, significantly increasing affordability and access for millions battling Type 2 diabetes and obesity.

Major Indian drugmakers gearing up to launch their generic semglutide injection in the country in March include Sun Pharmaceutical Industries, Zydus Lifesciences, Alkem Laboratories, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, and MSN Laboratories.

Obesity A Chronic Metabolic Condition

The CDSCO stressed the importance of "lifestyle modification measures (diet, exercise, behavioural interventions)" in treating obesity.

"Obesity is a chronic metabolic condition requiring comprehensive management, including lifestyle interventions," the regulator said.

"Pharmaceutical therapy, where indicated, must not be projected in a manner that undermines public health initiatives promoting diet control, physical activity, and preventive healthcare," it added.

WHO Guidelines On GLP-1 drugs

Amid increasing prevalence of GLP-1 drugs, the World Health Organisation (WHO), late last year, acknowledged its role in treating obesity.

However, it warned that medications like GLP-1 alone will not solve the problem affecting more than one billion people worldwide.

The global health body also issued conditional recommendations for using these therapies as part of a comprehensive approach that includes healthy diets, regular physical activity, and support from health professionals.

The UK Health Security Agency (HSA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have warned people against using non-sterile alcohol-free wipes in their homes and first aid kits, over their link to a fatal bacterial infection, which has also led to death in the country.

After testing almost 200 products, the officials identified Burkholderia stabilis -- a type of bacteria found naturally in the environment, including in soil and water -- in four brands of skin cleansing wipes intended for first aid.

These brands of non-sterile alcohol-free wipes have been contaminated and have caused serious infection with the B. stabilis. These include:

• ValueAid Alcohol Free Cleansing Wipes
• Microsafe Moist Wipe Alcohol Free
• Steroplast Sterowipe Alcohol Free Cleansing Wipes
• Reliwipe Alcohol Free Cleansing Wipes

While B. stabilis rarely causes infection in healthy individuals, it can be dangerous to people with a weakened immune system, cystic fibrosis, or malignancy, the authorities said. Further, patients using intravenous lines at home are also at higher risk of developing infection.

The MHRA had, in 2025, also issued a warning against the four products.

“There have been 59 confirmed cases of Burkholderia stabilis associated with some non-sterile alcohol-free wipe products -- identified in an outbreak in the United Kingdom from January 2018 to 3 February 2026,” the joint statement said.

“A small number of cases continue to be detected. These have included some serious infections which have required hospital treatment, and one death has been attributed to Burkholderia stabilis infection,” it added.

The health agencies also stressed that only wipes marked as “sterile” should be used on broken skin and only used to clean intravenous lines if instructed by a patient’s medical team.

“We are reminding the public not to use, and to dispose of, certain non-sterile alcohol-free wipes, which have been linked to an outbreak of Burkholderia stabilis,” said James Elston, consultant in epidemiology and public health at UKHSA.

“Those who still have any of the affected products should stop using them immediately and dispose of them in standard household waste,” the UKHSA added.

A recent report by Eurosurveillance, early this month, also confirmed 59 cases of B. stabilis associated with contaminated non-sterile alcohol-free wipe products in the UK as of February.

Also read: What Kind Of Wipes Should You Use To Clean Wounds? Here's What UKHSA Suggests

Key Symptoms To Watch For

Anyone who has used non-sterile, alcohol-free wipes does not need to seek medical care unless they develop symptoms of infection, such as:

Wound infection: redness, swelling, warmth, increased pain, or pus/drainage from the site

Infection involving an IV line: redness, swelling, or pain at the insertion site, along with fever or chills

Safety Advice by UKHSA And MHRA

The UKHSA offers the following guidance for safe wipe use:

• Use only sterile wipes on broken skin, wounds, or scratches to reduce the risk of germs entering the body.
• Check that your first aid kit contains only wipes labelled “sterile,” ensure the packaging is intact, and dispose of any out-of-date or damaged products.
• Only use wipes on IV lines if specifically instructed by your healthcare team.

Dr Alison Cave, MHRA Chief Safety Officer, emphasized that wipes intended for medical purposes are classed as medicines.

These products do not have the necessary medicines authorization, and steps are being taken to enforce compliance.

“If you have these wipes at home or in a first aid kit, check the label and only use wipes marked as ‘sterile’ on broken skin,” Dr. Cave advised.

“Healthcare professionals should follow instructions provided in the national patient safety alert.”

Anyone who has used alcohol-free wipes and is concerned about possible infection should speak to a healthcare professional.